These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11243965)

  • 1. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates.
    Bock NN; Rogers T; Tapia JR; Herron GD; DeVoe B; Geiter LJ
    Chest; 2001 Mar; 119(3):833-7. PubMed ID: 11243965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons.
    Lobato MN; Reves RR; Jasmer RM; Grabau JC; Bock NN; Shang N;
    Chest; 2005 Apr; 127(4):1296-303. PubMed ID: 15821208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lincoln T; Brannan GL; Lynch V; Conklin TJ; Clancey T; Rose DN; Tuthill RJ
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):306-11. PubMed ID: 15139468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong.
    Leung CC; Law WS; Chang KC; Tam CM; Yew WW; Chan CK; Wong MY
    Chest; 2003 Dec; 124(6):2112-8. PubMed ID: 14665488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients].
    Rivero A; López-Cortés L; Castillo R; Verdejo J; García MA; Martínez-Marcos FJ; Díez F; Escribano JC; Canueto J; Lozano F; Pasquau J; Hernández JJ; Márquez M; Kindelán JM;
    Enferm Infecc Microbiol Clin; 2007 May; 25(5):305-10. PubMed ID: 17504683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
    Tortajada C; Martínez-Lacasa J; Sánchez F; Jiménez-Fuentes A; De Souza ML; García JF; Martínez JA; Caylà JA;
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):276-81. PubMed ID: 15786890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Directly observed isoniazid preventive therapy for released jail inmates.
    Nolan CM; Roll L; Goldberg SV; Elarth AM
    Am J Respir Crit Care Med; 1997 Feb; 155(2):583-6. PubMed ID: 9032198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM; Lobato MN; Lang SG; Wheeler S; Kendig NE; Bur S
    J Public Health Manag Pract; 2019; 25(2):E1-E6. PubMed ID: 30024493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy].
    Rivero A; López-Cortés L; Castillo R; Lozano F; García MA; Díez F; Escribano JC; Canueto J; Pasquau J; Hernández JJ; Polo R; Martínez-Marcos FJ; Kindelán JM; Rey R;
    Enferm Infecc Microbiol Clin; 2003; 21(6):287-92. PubMed ID: 12809582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.
    Skevaki CL; Kafetzis DA
    Paediatr Drugs; 2005; 7(4):219-34. PubMed ID: 16117559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program.
    Priest DH; Vossel LF; Sherfy EA; Hoy DP; Haley CA
    Clin Infect Dis; 2004 Dec; 39(12):1764-71. PubMed ID: 15578397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
    Lee AM; Mennone JZ; Jones RC; Paul WS
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):995-1000. PubMed ID: 12475146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
    White MC; Tulsky JP; Lee JR; Chen L; Goldenson J; Spetz J; Kawamura LM
    J Correct Health Care; 2012 Apr; 18(2):131-42. PubMed ID: 22419641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
    Chan PC; Yang CH; Chang LY; Wang KF; Lu BY; Lu CY; Shao PL; Hsueh PR; Fang CT; Huang LM
    Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Latent tuberculosis infection: diagnosis and treatment].
    Bendayan D; Raz M; Kramer MR
    Harefuah; 2002 Mar; 141(3):233-6, 316. PubMed ID: 11944212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
    Adane K; Spigt M; Dinant GJ
    BMC Pulm Med; 2018 Feb; 18(1):37. PubMed ID: 29463234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.